Interleukin 28B polymorphism predicts interferon plus ribavirin treatment outcome in patients with hepatitis C virus-related liver cirrhosis: A multicenter retrospective study in Japan

Hepatology Research

Volumn 44, Issue 9, 2014, Pages 983-992

  Shakado, Satoshi ^a   Sakisaka, Shotaro ^a   Okanoue, Takeshi ^b   Chayama, Kazuaki ^d   Izumi, Namiki ^e   Toyoda, Joji ^f   Tanaka, Eiji ^g   Ido, Akio ^h   Takehara, Tetsuo ^c   Yoshioka, Kentaro ⁱ   Hiasa, Yoichi ^j   Nomura, Hideyuki ^k   Seike, Masataka ^l   Ueno, Yoshiyuki ^m   Kumada, Hiromitsu ⁿ  

^a FUKUOKA UNIVERSITY   (Japan)

^b Saiseikai Imperial Gift Foundation Inc Saiseikai Suita Hospital   (Japan)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d HIROSHIMA UNIVERSITY   (Japan)

^e MUSASHINO RED CROSS HOSPITAL   (Japan)

^f Sapporo Kousei Hospital   (Japan)

^g SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h KAGOSHIMA UNIVERSITY   (Japan)

ⁱ FUJITA HEALTH UNIVERSITY   (Japan)

^j EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^k Shin Kokura Hospital   (Japan)

^l OITA UNIVERSITY   (Japan)

^m YAMAGATA UNIVERSITY   (Japan)

ⁿ TORANOMON HOSPITAL   (Japan)

more..

Author keywords

Cirrhosis; Hepatitis C virus; Interferon; Interleukin 28B; Ribavirin

Indexed keywords

INTERFERON; INTERLEUKIN 28B; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ALLELE; ANEMIA; ARTICLE; BRAIN HEMORRHAGE; BRAIN INFARCTION; CHOLANGITIS; DECOMPENSATED LIVER CIRRHOSIS; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GASTROINTESTINAL DISEASE; HEART PALPITATION; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; INTERSTITIAL PNEUMONIA; JAPAN; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALAISE; MALE; MALIGNANT NEOPLASM; NONHUMAN; PRURITUS; RASH; RESPIRATORY TRACT DISEASE; RETINA HEMORRHAGE; RETROSPECTIVE STUDY; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; VIRUS LOAD;

EID: 84907875950     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12280     Document Type: Article

References (41)

1. Niederau C, Lange S, Heintges T etal. Progress of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998; 28: 1687-1695.
2. Fattovich G, Giustina G, Degos F etal. Morbidity and mortality in compensated cirrhosis type C; a retrospective follow up study of 384 paatients. Gastroenterology 1997; 112: 463-472.
3. Hu KQ, Tong MJ. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology 1999; 29: 1311-1316.
4. Sangionvanni A, Prati GM, Fasani P etal. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology 2006; 43: 1303-1310.
5. Nishiguchi S, Kuroki T, Nakatani S etal. Randomized trail of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051-1055.
6. Shiratori Y, Ito Y, Yokosuka O etal. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved. Ann Int Med 2005; 142: 105-114.
7. Bruno S, Stroffolini T, Colombo M etal. Sustained virological response to interferon-alpha is associated with improved outcome in HCV related cirrhosis: a retrospective study. Hepatology 2007; 45: 579-587.
8. Wright TL. Treatment of patients with hepatitis C and cirrhosis. Hepatology 2002; 36: S185-194.
9. Manns MP, McHutchison JG, Gordon SC etal. Peginterferon alpha-2b plus ribavirin compared with interferon aalpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958-965.
10. Bota S, Sporea I, Popescu A etal. Response to standard of care antiviral treatment in patients with HCV liver cirrhosis - a systematic review. J Gastrointestin Liver Dis 2011; 20: 293-298.
11. Ge D, Fellay J, Thompson AJ etal. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
12. Tanaka Y, Nishida N, Sugiyama M etal. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-1109.
13. Suppiah V, Moldovan M, Ahlenstiel G etal. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-1104.
14. Ziol M, Handra-Luca A, Kettaneh A etal. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005; 41: 48-54.
15. Castera L, Vergniol J, Foucher J etal. Prospective comparison of transient elastography, fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343-350.
16. Ikeda K, Saitoh S, Kobayashi M etal. Distinction between chronic hepatitis and liver cirrhosis in patients with hepatitis C virus infection. Practical discriminant function using common laboratory data. Hepatol Res 2000; 18: 252-266.
17. Ohnishi Y, Tanaka T, Ozaki K, Yamada R, Suzuki H, Nakamura Y. A high-throughput SNP typing system for genome-wide association studies. J Hum Genet 2001; 46: 471-477.
18. Suzuki A, Yamada R, Chang X etal. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginie deminase 4, are associated with rheumatoid arthritis. Nat Genet 2003; 34: 395-402.
19. Kawaoka T, Hayes CN, Ohishi W etal. Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotype 2a and 2b. J Hepatol 2010; 54: 408-414.
20. Sarrazin C, Susser S, Doehring A etal. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol 2010; 54: 415-421.
21. Asselah T, De Muynck S, Broët P etal. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol 2012; 56: 527-532.
22. De Nicola S, Aghemo A, Rumi MG etal. Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4. Hepatology 2012; 55: 336-342.
23. Akuta A, Suzuki F, Seko Y etal. Association of IL28B genotype and viral response of hepatitis C virus genotype 2 to interferon plus ribavirin combination therapy. J Med Virol 2012; 84: 1593-1599.
24. Montes-Cano MA, Garcia-Lozano JR, Abad-Molina C etal. Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology 2010; 52: 33-37.
25. Yu ML, Huang CF, Huang JF etal. Role of interleukin-28B polymorphism in the treatment of hepatitis C virus genotype 2 infection in Asian patients. Hepatology 2011; 53: 7-13.
26. Thomas DL, Thio CL, Martin MP etal. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.
27. Yang M, Rao HY, Feng B, Zhang W, Wei L. The impact of IL28B polymorphisms on spontaneous clearance of hepatitis C virus infection: a meta-analysis. J Gastroenterol Hepatol 2013; 28: 1114-1121.
28. Hadziyannis SJ, Sette H Jr, Morgan TR etal. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355.
29. McHutchison JG, Lawitz EJ, Shiffman ML etal. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580-593.
30. Lok AS, Everhart JE, Wright EC etal. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology 2011; 140: 840-849.
31. Fried MW, Shiffman ML, Reddy KR etal. Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
32. McHutchison JG, Lawitz EJ, Shiffman ML etal. Peginterferon alfa-2b with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580-593.
33. Bota S, Sporea I, Sirli R etal. Severe adverse events during antiviral therapy in hepatitis C virus cirrhotic patients: a systematic review. World J Hepatol 2013; 27: 120-126.
34. Buti M, Valdés A, Sánchez-Avila F, Esteban R, Lurie Y. Extending combination therapy with peginterferon alfa-2b plus ribavirin for genotype 1 chronic hepatitis C late responders: a report of 9 cases. Hepatology 2003; 37: 1226-1227.
35. Berg T, von Wagner M, Nasser S etal. Extended treatment duration for hepatitis C virus type 1: comparing 48 weeks versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006; 130: 1086-1097.
36. Sanchez-Tapias JM, Diago M, Escartin P etal. Peginterferon-alfa-2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006; 131: 451-460.
37. Akuta N, Suzuki F, Hirakawa M etal. A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitution in HCV core region as predictor of sustained virological response. J Med Virol 2009; 81: 452-458.
38. Poordad F, Lawitz E, Kowdley KV etal. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med 2013; 368: 45-53.
39. Zeuzem S, Soriano V, Asselah T etal. Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med 2013; 369: 630-639.
40. Gane EJ, Stedman CA, Hyland RH etal. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013; 368: 34-44.
41. Suzuki Y, Ikeda1 K, Suzuki F etal. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infected and limited treatment options. J Hepatol 2013; 58: 655-662.